Production of a polyclonal antibody against osteogenic protein-1, and its role in the diagnosis of osteoarthritis

Sonam Choden Bhutia1, BSc, MSc, Takhelmayum Amumacha Singh2, MBBS, MD, Mingma Lhamu Sherpa2, MBBS, MD

INTRODUCTION Osteoarthritis (OA) of the knee is a degenerative joint disease that is predominantly seen in the elderly population. It is mainly caused by the degradation of articular cartilage and is most commonly attributed to imbalances between anabolic and catabolic processes. While the prevalence of OA in India is reported to be 17.0%–60.6%, this range is based on studies conducted in Maharashtra and Amritsar, and not a pan-India study.

Although radiography is the usual method for diagnosing OA, it has been shown to have a poor association with the clinical features of OA. A simpler and more sensitive means of diagnosing OA is required. Cartilage-derived molecules present in the synovial fluid may act as a marker of the biosynthetic or degradative changes that occur during OA. Recently, osteogenic protein-1 (OP-1), a member of the bone morphogenetic protein (BMP) family, has shown a great potential for cartilage repair due to its anabolic and anticitabolistic effects on cartilage. The cost of producing OP-1 is one of the major barriers for its use in the management of OA. With knowledge regarding the beneficial effects of OP-1 in cartilage regeneration and repair, it has become important to be able to estimate the concentration of OP-1 in osteoarthritic patients in a simple and feasible manner. In the present study, we attempted to isolate OP-1 from the synovial fluid of osteoarthritic patients. The isolated OP-1 was then used to immunise mice intraperitoneally for the purpose of producing polyclonal antibodies (anti-OP-1[f]) immunoglobulin G (IgG) able to detect the antigenic OP-1 in osteoarthritic patients by sandwich enzyme-linked immunosorbent assay (ELISA).

METHODS This was an experimental study conducted at the Department of Biochemistry, Sikkim Manipal Institute of Medical Sciences, India. Polyclonal antibodies (i.e. anti-OP-1[f]) were raised against OP-1 in mice, and subsequently used in a sandwich enzyme-linked immunosorbent assay (ELISA) to detect the presence of OP-1 in the synovial fluids of 75 osteoarthritic patients. For the purpose of correlation, the radiographic assessments of the knees of the 75 patients were graded using the Kellgren-Lawrence scoring system.

RESULT The polyclonal antibody (i.e. anti-OP-1[f]) raised against OP-1 was able to detect the presence of OP-1 in the synovial fluids of all the osteoarthritic patients via sandwich ELISA. The level of the OP-1 was found to be much higher than the reference range and correlated positively with the severity of OA (r = 0.24; p = 0.04).

CONCLUSION Our study shows that the polyclonal antibody, anti OP-1(f), could be used for the immunodiagnosis of osteoarthritis via sandwich ELISA.

Keywords: osteoarthritis, osteogenic protein-1, sandwich ELISA, synovial fluid

1Department of Biochemistry, Sikkim Manipal Institute of Medical Sciences, Sikkim, India
Correspondence: Dr Mingma Lhamu Sherpa, Professor, Department of Biochemistry, Sikkim Manipal Institute of Medical Sciences, Gangtok 737102, Sikkim, India. mingmals@yahoo.com

DOI: 10.11622/smedj.2014092
OP-1(f) was used as the immunogen after it had been mixed to the procedure described by Cheirmaraj et al. Each of the 12 equal gel fractions at a dilution of 1:600 for the Sandwich ELISA was performed to check the reading of OP-1 in intervals and were designated OP-1(a) to OP-1(l). Each of the fractions was mechanically ground and transferred to 5 mL of blue R-250 for approximately one hour and then destained; the dye reached 12 cm in the separating gel. Molecular weight markers (3 kD–205 kD) (Bangalore Genie Ltd, Bangalore, India) were used for the calibration of the gel. After separation, the gel was cut into individual strips and blocked with PBS/T, with 0.5% gelatin at 37°C for two hours, followed by four extensive washes with PBS/T. The strips were incubated with HRP conjugated with anti-OP-1 for one hour. Antibody binding was revealed using diaminobenzidine (DAB) (HiMedia, Bangalore, India) in a Tris-glycine buffer, pH 8.3, at 25 mV for 1.5 hours. The electrophoresis run was continued until the tracking dye reached 12 cm in the separating gel. SDS-PAGE was performed according to the procedure described by Shapiro et al.35 stacked at a constant current of 50 mV. The electrophoresis run was continued until the tracking dye reached 12 cm in the separating gel. Molecular weight markers (3 kD–205 kD) (Bangalore Genie Ltd, Bangalore, India) were used for the calibration of the gel. After separation, the gel was cut into two parts – one part was stained with Coomassie® blue R-250 for approximately one hour and then destained; the other part was cut horizontally into 12 equal fractions at 1 cm intervals and were designated OP-1(a) to OP-1(l). Each of the 12 fractions was mechanically ground and transferred to 5 mL of 0.05 M sodium phosphate buffer (SPB), pH 7.2; the protein was allowed to elute overnight at 4°C.36 The eluants of the 12 fractions were then lyophilised and dialysed against 0.01 M SPB overnight. Protein concentrations were estimated using Lowry’s method.37 Sandwich ELISA was performed to check the reading of OP-1 in each of the 12 equal gel fractions at a dilution of 1:600 for the anti-OP-1-HRP-conjugate, and at 1:150 for the sample.

White albino female mice aged 8 weeks and weighing 40–42 g were used for immunisation. The animals were reared in the institutional animal house, SMIMS, as per the guidelines set by the Committee for the Purpose of Control and Supervision of Experiments on Animals.36 Polyclonal antibodies were raised against the OP-1(f) fraction in mouse ascitic fluid, according to the procedure described by Cheirmaraj et al.37 Purified OP-1(f) was used as the immunogen after it had been mixed with complete Freund’s adjuvant (CFA) (Bangalore Genie Ltd, Bangalore, India) in the ratio of 4:1. The mice were immunised intraperitoneally with high titres of CFA with protein on Days 0, 14, 21, 28 and 35. Each mouse received 195 µg of the purified protein (OP-1) in five doses. A single dose of 500 µL of pristane (2,6,10,14-tetramethyl pentadecane) (HiMedia, Bangalore, India) was administered with the second dose of CFA with protein. The ascitic fluid produced in the peritoneal cavity of the mice was collected at weekly intervals from Day 28 to Day 56 by abdominal tapping. Peritoneal cells and lipids were separated from the ascitic fluid by centrifugation at 3,000 rpm. The presence of anti-OP-1(f) IgG in the ascitic fluid was detected with indirect ELISA using OP-1(f) at a dilution of 1:100, and anti-human IgG HRP conjugate (Bangalore Genie Ltd, Bangalore, India) at a dilution of 1:1200.

The immunoglobulins were separated from the ascitic fluid by saturation with 35%–75% ammonium sulphate (Merck, Mumbai, India) according to the procedure described by Reddy et al.38 The precipitate was centrifuged at 8,000 rpm for 15 mins at 4°C, washed with 40% ammonium sulphate solution, reconstituted in a small volume of 0.05 M SPB, and dialysed against 0.01 M SPB (pH 7.2) overnight at 4°C. The protein concentration was estimated, and the protein was designated as anti-OP-1(f) IgG. The protein was stored at –20°C after the addition of 0.1% sodium azide (Merck, Mumbai, India) as a preservative.

The OP-1 concentration of the synovial fluids from the 75 osteoarthritic patients was detected with sandwich ELISA, using anti-OP-1(f) and anti-OP-1 (sc-9305) conjugated with HRP. To calculate the concentrations of the OP-1 in the synovial fluids, a standard curve was prepared using a known concentration of OP-1 (78.4 µg/mL) diluted in PBS/T to a concentration ranging from 0 ng/mL to 250 ng/mL. The OP-1 concentrations in the synovial fluids of the 75 clinically diagnosed osteoarthritic patients were determined using sandwich ELISA, using anti-OP-1(f) and anti-OP-1 (sc-9305) conjugated with HRP. The correlation between the concentration of OP-1 in the synovial fluid and the severity of OA was determined using the Spearman’s rank correlation coefficient. Comparisons of the OP-1 levels among the different stages of OA by KL grading were analysed using one-way analysis of variance (ANOVA). Data was expressed as mean ± standard deviation, and a p-value < 0.05 was considered statistically significant.

**RESULTS**

The OP-1 concentrations in the synovial fluids from the 75 osteoarthritic patients were determined using sandwich ELISA. The highest absorbance was noted for the 1:150 dilution of the sample and the 1:200 dilution of the enzyme-antibody conjugate, using the checkerboard titration described in the Methods section. As sample no. 25 showed the highest concentration of OP-1 (230 ng/mL), it was selected for use in the subsequent analysis. Western blot was done to confirm the presence of OP-1 (Fig. 1). Among the 12 SDS-PAGE fractions, the OP-1(f) fraction had the highest concentration of OP-1 (45 ng/mL), with a molecular weight of about 36 kD (Fig. 2). The protein concentration of the same fraction, estimated using Lowry’s...
method, was found to be 78.4 µg/mL. This fraction (i.e. OP-1[f]) was purified and used to immunise the mice.

Approximately 11 mL of total ascitic fluid was collected from each mouse. The level of IgG antibody collected was estimated using indirect ELISA from Day 28 (absorbance = 0.356) to Day 56 (absorbance = 1.679); the level of antibodies increased from Day 28 to Day 56. IgG antibody concentration could not be determined due to the lack of a standard for anti-OP-1(f) IgG. However, for the purpose of the present study, we assumed that the absorbance was directly proportional to the concentration of anti-OP-1(f) IgG. Using Lowry’s method, the protein concentration of anti-OP-1(f) was 125 µg/mL.

The mean OP-1 concentration in the synovial fluid of the 75 osteoarthritic patients, obtained using sandwich ELISA, was 92.8 ± 39.7 ng/mL. This value is much higher than the normal value of about 50 ng/mL (19,20). The concentration of OP-1 observed using commercially available anti-OP-1 and using anti-OP-1(f) IgG gave similar readings among the 75 samples of synovial fluid. According to the KL grading, 10 out of the 75 osteoarthritic patients were diagnosed with grade I OA, 27 with grade II OA, 23 with grade III OA, and 15 with grade IV OA (Table I & Fig. 3). When the OP-1 levels of the synovial fluid were compared with the radiological KL grading for OA, a significant positive correlation between OP-1 levels of synovial fluid and OA severity (r = 0.24; p = 0.04) was found. Although the concentration of OP-1 was found to be higher in grades III and IV OA, the difference was not statistically significant (p > 0.05).

**DISCUSSION**

The presence of endogenous OP-1 in human synovial fluid has been studied. In the present study, the sample with the highest OP-1 concentration among the 75 clinically diagnosed osteoarthritic patients (i.e. sample no. 25) was isolated and used to immunise mice intraperitoneally for the production of polyclonal antibodies (anti-OP-1). Among the 12 SDS-PAGE fractions isolated, the antigenic fraction, OP-1(f), had an approximate molecular weight of 36 kD. Previous studies have shown that the molecular weight of OP-1 in osteoarthritic patients was around 18–36 kD (19,20).

The antibody produced in the present study (i.e. anti-OP-1[f] IgG) was found to be useful for the detection of OP-1 in the synovial fluid of osteoarthritic patients. Through the preparation of standards using a known concentration of OP-1 (78.4 µg/mL), we also attempted to measure the concentration of OP-1 in the

<table>
<thead>
<tr>
<th>Grade of osteoarthritis</th>
<th>OP-1 (ng/mL)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade I (n = 10)</td>
<td>74.6 ± 24.8</td>
</tr>
<tr>
<td>Grade II (n = 27)</td>
<td>85.0 ± 32.5</td>
</tr>
<tr>
<td>Grade III (n = 23)</td>
<td>103.0 ± 42.5</td>
</tr>
<tr>
<td>Grade IV (n = 15)</td>
<td>103.0 ± 50.0</td>
</tr>
</tbody>
</table>

Note: One-way ANOVA p-value = 0.09. *Data is presented as mean ± standard deviation.

![Fig. 1 Image of the Western blot used in the qualitative detection of osteogenic protein-1 using diaminobenzidine substrate.](image1)

![Fig. 2 Image of the SDS-PAGE gel. Lane M: molecular weight markers; lane 1: osteogenic protein-1 (a) to (l).](image2)

![Fig. 3 Graph shows the association between the concentration of osteogenic protein-1 (OP-1) in synovial fluid and the different grades of osteoarthritis (OA), according to the Kellgren-Lawrence grading system.](image3)
synovial fluid of the 75 osteoarthritic patients. We found that the level of the OP-1 in our study cohort was high compared to normal values (i.e. about 50 ng/mL). An increase in OP-1 levels has also been observed in other studies. In the present study, we found a significant positive correlation between the OP-1 level in the synovial fluids of osteoarthritic patients and OA severity, similar to the results of a study by Honsawek et al. This correlation could be due to an increased expression and production of OP-1 in the extracellular matrix, in an autocrine or a paracrine manner. A previous study reported that OP-1 level increases in response to inflammation in OA. In the present study, we found that the OP-1 level in the synovial fluids of patients with grades III and IV OA was higher than in those with grades I and II OA. However, this difference was not statistically significant.

A limitation of the present study is that statistical comparisons between the OP-1 level in synovial fluids from osteoarthritic patients and that in synovial fluids from normal joints could not be done due to ethical reasons. Comparisons using computed tomography and magnetic resonance imaging were also not done due to the unavailability of such facilities. Furthermore, as this was an experimental study with an observational, cross-sectional design, and knee replacement surgery facilities were not available in the country, comparisons of OP-1 levels before and after surgery could not be done. The present study did not analyse the changes in OP-1 levels with exercise, as it was a cross-sectional study.

In conclusion, the present study shows that polyclonal antibodies, such as anti-OP-1(f), can be produced against an antigenic fraction (e.g. OP-1(f)) of synovial fluids from osteoarthritic patients. These polyclonal antibodies could be used for the immunodiagnosis of osteoarthritis, as the level of OP-1 correlates positively with OA severity. Further research studying the differences among the OP-1 levels of synovial fluids from normal joints of different ages and genders, as well as longitudinal studies analysing OP-1 levels before and after treatment, would be required before OP-1 can be used as a marker of OA status and prognosis.

ACKNOWLEDGEMENT
The authors wish to express their gratitude to the North Eastern Region of Biotechnology Management Programme, DBT India for the grant under the Institutional Level Biotechnology Hub Project.

REFERENCES